Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Edivoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 17/20 | 0.87 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.40 |
| ▸ | CDK9 | P50750 | 2/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edivoxetine SCHEMBL14072285 | 0.99 | SLC6A2 (0.89) | SLC6A2SLC6A4SLC6A3HRH1CCNT1 | |
| Edivoxetine SCHEMBL17662033 | 0.99 | SLC6A2 (0.89) | SLC6A2SLC6A4SLC6A3HRH1CCNT1 | |
| Edivoxetine SCHEMBL13176435 | 0.99 | SLC6A2 (0.89) | SLC6A2SLC6A4SLC6A3HRH1CCNT1 | |
| Edivoxetine SCHEMBL2907186 | 0.99 | SLC6A2 (0.89) | SLC6A2SLC6A4SLC6A3HRH1CCNT1 | |
| Hydrochloric Acid SCHEMBL2907982 | 0.94 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3HRH1CCNT1 | |
| SCHEMBL2909340 | 0.93 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3HRH1CCNT1 | |
| Hydrochloric Acid SCHEMBL2909359 | 0.84 | SLC6A2 (0.71) | SLC6A2SLC6A4SLC6A3ADRA2C | |
| SCHEMBL30818447 | 0.83 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3HRH1CCNT1 | |
| SCHEMBL29221485 | 0.83 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3HRH1CCNT1 | |
| SCHEMBL29221482 | 0.83 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3HRH1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2223916-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | Eli Lilly and Company (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-1682523-B1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | LILLY CO ELI (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7423037-B2 | e.g. 1-[1,1'-biphenyl]-2-yl-2-morpholin-2-ylpropan-2-ol; antidepressant, anxiolytic agent, cognition activator | ELI LILLY AND COMPANY (US) | 2008-09-09 | — | — | US | disclosed |
| US-20070083046-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070083046-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | SLC6A2, SLC18A2, SLC6A3 | SLC6A2 1/4885SLC6A4 4/4885SLC6A3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.